• News
  • General

Halozyme Therapeutics recommended for European Commission approval

San Diego-based Halozyme Therapeutics Inc. (Nasdaq: HALO) announced Friday the EU Committee for Medicinal Products for Human Use has recommended that the European Commission approved its treatment of common forms of non-Hodgkin lymphoma.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!